SION · Company research
Sionna Therapeutics, Inc. (SION): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
19records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| SION Jan 2027 70.000 put (SION270115P00070000) Stock Historical Prices & Data - Yahoo! Finance Canada | SION Jan 2027 70.000 put (SION270115P00070000) Stock Historical Prices & Data Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 18, 2026 | neutral | 0 | 0.6 |
| SION Oct 2026 2.500 call (SION261016C00002500) Stock Historical Prices & Data - Yahoo Finance | SION Oct 2026 2.500 call (SION261016C00002500) Stock Historical Prices & Data Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| SION Oct 2026 7.500 put (SION261016P00007500) Stock Historical Prices & Data - Yahoo! Finance Canada | SION Oct 2026 7.500 put (SION261016P00007500) Stock Historical Prices & Data Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 15, 2026 | neutral | 0 | 0.6 |
| Sionna Therapeutics, Inc. (SION) Loses 37.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance | Sionna Therapeutics, Inc. (SION) Loses 37.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Yahoo Finance | View source ↗ | Yahoo Finance | Oct 12, 2026 | neutral | 0 | 0.6 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION | Pomerantz LLP is investigating potential securities fraud claims against Sionna Therapeutics following the company's August 10, 2026 announcement that its PreciSION CF Phase 2a trial failed to achieve its key activity endpoint. The failure to demonstrate efficacy of SION-719 when combined with Trikafta resulted in a dramatic 91.18% stock price decline, falling from approximately $51.04 to $4.50 per share. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bearish | -1 | 1 |
| INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION | Pomerantz LLP is investigating potential securities fraud claims against Sionna Therapeutics following the company's August 10, 2026 announcement that its PreciSION CF Phase 2a trial failed to achieve its key activity endpoint. The failure to demonstrate efficacy of SION-719 when combined with Trikafta resulted in a dramatic 91.18% stock price decline, falling from approximately $51.04 to $4.50 per share. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | bearish | -1 | 1 |
| Sionna Therapeutics (NasdaqGM:SION) Stock Price - Simply Wall Street | Sionna Therapeutics (NasdaqGM:SION) Stock Price Simply Wall Street | View source ↗ | Simply Wall Street | Oct 5, 2026 | neutral | 0 | 0.6 |
| RA Capital’s Sionna (NASDAQ: SION) stock sale wasn’t under a preset trading plan - Stock Titan | RA Capital’s Sionna (NASDAQ: SION) stock sale wasn’t under a preset trading plan Stock Titan | View source ↗ | Stock Titan | Sep 21, 2026 | neutral | 0 | 0.6 |
| $SION stock is down 13% today. Here's what we see in our data. - Quiver Quantitative | $SION stock is down 13% today. Here's what we see in our data. Quiver Quantitative | View source ↗ | Quiver Quantitative | Sep 15, 2026 | neutral | 0 | 0.6 |
| $SION stock is down 9% today. Here's what we see in our data. | SION Stock News - Quiver Quantitative | $SION stock is down 9% today. Here's what we see in our data. | SION Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 20, 2026 | neutral | 0 | 0.6 |
| Sionna Therapeutics (SION) Securities Investigation Notice - Levi & Korsinsky - PR Newswire | Sionna Therapeutics (SION) Securities Investigation Notice - Levi & Korsinsky PR Newswire | View source ↗ | PR Newswire | Aug 19, 2026 | neutral | 0 | 0.6 |
| Sionna Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Sionna Therapeutics (SION) - PR Newswire | Sionna Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Sionna Therapeutics (SION) PR Newswire | View source ↗ | PR Newswire | Aug 12, 2026 | neutral | 0 | 0.6 |
| SION Stock Slides, Then Snaps Back As Traders Eye Volatility - StocksToTrade | SION Stock Slides, Then Snaps Back As Traders Eye Volatility StocksToTrade | View source ↗ | StocksToTrade | Aug 11, 2026 | neutral | 0 | 0.6 |
| Sionna Therapeutics stock falls 92% after SION-719 trial failure - Quartz | Sionna Therapeutics stock falls 92% after SION-719 trial failure Quartz | View source ↗ | Quartz | Aug 11, 2026 | neutral | 0 | 0.6 |
| Why Sionna Therapeutics Stock Is Crashing 91% to a Record Low - Barron's | Why Sionna Therapeutics Stock Is Crashing 91% to a Record Low Barron's | View source ↗ | Barron's | Aug 10, 2026 | neutral | 0 | 0.6 |
| Sionna’s cystic fibrosis flop sends stock down 90%, but a ‘significant positive’ for Vertex - Fierce Biotech | Sionna’s cystic fibrosis flop sends stock down 90%, but a ‘significant positive’ for Vertex Fierce Biotech | View source ↗ | Fierce Biotech | Aug 10, 2026 | neutral | 0 | 0.6 |
| SION Stock Draws Focus As Data Overhang Hits Vertex - StocksToTrade | SION Stock Draws Focus As Data Overhang Hits Vertex StocksToTrade | View source ↗ | StocksToTrade | Aug 10, 2026 | neutral | 0 | 0.6 |
| SION Stock On Track For Worst Day Ever After 90% Drop — What’s Driving The Selloff? - Stocktwits | SION Stock On Track For Worst Day Ever After 90% Drop — What’s Driving The Selloff? Stocktwits | View source ↗ | Stocktwits | Aug 10, 2026 | neutral | 0 | 0.6 |
| Sionna Won’t Advance Add-On Drug After CF Trial Misses Goal - Stock Titan | Sionna Won’t Advance Add-On Drug After CF Trial Misses Goal Stock Titan | View source ↗ | Stock Titan | Aug 10, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.